Actelion Pharmaceuticals is Pharmaceuticals in Switzerland that focus on actelion business. Founded in 1997. They cover business area such as actelion, several product, pulmonary arterial hypertension, Tracleer, Opsumit, Uptravi, Ventavis, Veletri, various stage, different method, administration, Zavesca, a second-line option, Gaucher disease, Valchlor, blood cancer, its approve orphan drug, its internal pipeline, in-licensing, acquisition.
1997
( 27 years old in 2024 )
Actelion
-
Gewerbestrasse 16
4123 Allschwil
Switzerland
Private
actelionseveral productpulmonary arterial hypertensionTracleerOpsumitUptraviVentavisVeletrivarious stagedifferent methodadministrationZavescaa second-line optionGaucher diseaseValchlorblood cancerits approve orphan drugits internal pipelinein-licensingacquisition
* We use standard office opening hours in near Actelion Pharmaceuticals's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Actelion Pharmaceuticals is Pharmaceuticals business from Switzerland that founded in 1997 (27 years old in 2024), Actelion Pharmaceuticals business is focusing on Actelion.
Actelion Pharmaceuticals headquarter office and corporate office address is located in Gewerbestrasse 16 4123 Allschwil Switzerland.
Actelion Pharmaceuticals was founded in Switzerland.
In 2024, Actelion Pharmaceuticals is currently focus on actelion sector.
Above is snippet of Google Trends for "actelion" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Actelion Pharmaceuticals, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
